HIV-HCV Coinfection

•Does Prior Use of Protease Inhibitors for HIV Therapy Affect Response to Experimental HCV PIs?  11/14/06
•Liver Transplantation in HIV Positive Patients  11/14/06
•

Serum Markers for Assessment of Liver Fibrosis in HIV-HCV Coinfected Patients  11/10/06

•istological Response to Pegylated Interferon plus Ribavirin in HIV-HCV Coinfected Individuals  11/07/06
•Impact of Coinfection with HIV on Early Immune Response to HCV  11/07/06
•Cyclophilin inhibitor DEBIO-025 Active against both HCV and HIV in Coinfected Individuals  11/07/06
•

Positive Impact of Higher Ribavirin Doses and Longer Duration of Therapy with Pegasys plus Ribavirin in HIV/HCV Coinfected Patients: The PRESCO Trial  11/07/06

•Liver Steatosis in HIV-HCV Coinfected Patients in France  10/31/06
•Impact of Coinfection with HIV on Early Immune Response to HCV  10/31/06
•Cyclophilin inhibitor DEBIO-025 Active Against both HCV and HIV in Coinfected Individuals  10/31/06
•Positive Impact of Higher Ribavirin Doses and Longer Duration of Therapy with Pegasys plus Ribavirin in HIV/HCV Coinfected Patients: The PRESCO Trial  10/31/06
•Can HIV-HCV Coinfection Be Effectively Treated in Community Based Clinics?  10/31/06
•Survival of HIV-HCV Coinfected Patients after Liver Transplantation  10/31/06



Google_______________


 

 

 

 

 

 

 

 

 


Conference
Main Page

Hepatitis C
FDA-Approved
Treatments

Monotherapies
Intron A
Roferon
Infergen
Pegasys
PEG-Intron

Combination
 Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin

Hepatitis B
FDA-Approved
Treatments

Baraclude
 Epivir-HBV
 Hepsera
 Intron A
 Pegasys
 Tyzeka